The impact of the ‘Better Care Better Value’ prescribing policy on the utilisation of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for treating hypertension in the UK primary care setting: longitudinal quasi-experimental design

Table 4 Segmented regression analysis on the monthly cost of ACEIs/ARBs, ACEIs and ARBs

Variables	β₁^(a)	β₂^(b)	β₃^(c)	β₄^(d)	β₅^(e)	β₆^(f)	β₇^(g)
ACEIs/ARBs	22072 (15546,28599)	---	---	−287538 (−368885,-206192)	−15970 (−21775,-10164)	−266656 (−349379,-183932)	−15019 (−22054,-7983)
ACEIs	6228.8 (4372, 8086)	---	---	---	---	−286941 (−308447,-265435)	−6094 (−7971,-4217)
ARBs	17030 (13449, 20611)	---	---	−298044 (−357163, −238924)	−15548 (−19712,-11384)	---	−9839 (−14560,-5118)

Regression coefficients (95 % confidence intervals) for the final model (the most parsimonious models); ^(a) baseline trend; ^(b) level change following BCBV policy; ^(c) trend change following BCBV policy; ^(d) level change following generic losartan availability; ^(e) trend change following generic losartan availability; ^(f) level change following generic perindopril availability; ^(g) trend change following generic perindopril availability; −--: indicates insignificant estimates at 0.05 level, after stepwise backward elimination; ACEIs: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin receptor blockers

ISSN: 1472-6963